🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Melbourne
Clinical trial register · Australia

Clinical Trials in Melbourne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 37 Clayton 21 Murdoch 19 Camperdown 17 Heidelberg 16
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca54 Janssen Research & Development, LLC37 Merck Sharp & Dohme LLC32 Peter MacCallum Cancer Centre, Australia31 Novartis Pharmaceuticals28 Clear sponsor filter
Site location
Melbourne37 Clayton21 Murdoch19 Camperdown17 Heidelberg16
All 73 locations
Target enrolment
to

Trials with a site in Melbourne

37 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Darlinghurst, Garran, Heidelberg, Macquarie University, Melbourne, Perth, Port Macquarie
2026-05-31
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Melbourne
2026-05-13
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Box Hill, Brisbane, Clayton, Fitzroy, Melbourne, Murdoch, Nedlands, Southport
2026-02-04
Recruiting
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT07308132Lymphoma, Non-Hodgkin
DrugsJNJ-87801493·Loncastuximab Tesirine·Polatuzumab Vedotin·Vincristine
Janssen Research & Development, LLC
Phase 1
340
Clayton, Melbourne, North Ryde, Randwick
2026-01-20
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Heidelberg, Kurralta Park, Melbourne, Wahroonga, Woolloongabba
2025-12-19
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Clayton, Liverpool, Melbourne, Murdoch, St Leonards
2025-12-03
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Heidelberg, Kurralta Park, Melbourne, Murdoch, Woolloongabba
2025-09-02
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Bedford Park, Camperdown, Fitzroy, Kogarah, Melbourne, Woolloongabba
2025-06-04
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Clayton, Coorparoo, Greenslopes, Kogarah, Melbourne, Mitcham, Westmead
2025-04-15
Active, closed
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
DrugsAzacitadine·Venetoclax
Janssen Research & Development, LLC
Phase 1
85
Concord, Melbourne, Nedlands
2025-03-21
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Macquarie University, Melbourne, Nedlands, Randwick
2024-12-30
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
DrugsRamantamig·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 1
276
Clayton, Fitzroy, Melbourne, Waratah, Wollongong
2024-12-04
Active, closed
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895Multiple Myeloma
DrugsCilta-cel·Talquetamab
Janssen Research & Development, LLC
Phase 2
11
Camperdown, Heidelberg, Melbourne
2024-09-16
Active, closed
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025Multiple Myeloma
DrugsCilta-cel·Talquetamab·Teclistamab·Bortezomib
Janssen Research & Development, LLC
Phase 2
43
Melbourne
2024-08-20
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Benowa, Clayton, Kogarah, Melbourne, Mitcham, Parkville
2024-03-09
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Campbelltown, Canberra, East Melbourne, Greenslopes, Melbourne
2024-01-17
Active, closed
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
NCT06139406Lymphoma, Non-Hodgkin
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543
Janssen Research & Development, LLC
Phase 1
70
Heidelberg, Melbourne, Nedlands, Randwick
2023-12-06
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
DrugsJNJ-101556143·JNJ-87189401·Lutetium Lu 177 vipivotide tetraxetan·Pasritamig
Janssen Research & Development, LLC
Phase 1
355
Greenslopes, Melbourne
2023-11-01
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
East Melbourne, Greenslopes, Melbourne, Miranda, Mitcham, Parkville
2023-10-12
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Macquarie University, Melbourne, South Brisbane
2023-08-31
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
DrugsJNJ-101556143·Lutetium Lu 177 vipivotide tetraxetan·Pasritamig·Cabazitaxel
Janssen Research & Development, LLC
Phase 1
300
Kurralta Park, Macquarie University, Melbourne, Woolloongabba
2023-04-26
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Blacktown, Fitzroy, Melbourne, Murdoch, Nedlands
2023-03-29
Active, closed
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903Leukemia, Myeloid, Acute
DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine
Janssen Research & Development, LLC
Phase 1
196
Clayton, Melbourne, Westmead
2022-10-04
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Melbourne, Parkwood
2022-09-23
Active, closed
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
DrugJNJ-80948543
Janssen Research & Development, LLC
Phase 1
167
Macquarie University, Melbourne, Nedlands, Randwick
2022-08-18
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
Fitzroy, Melbourne, Murdoch, Waratah
2022-08-12
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
Adelaide, Camperdown, Melbourne, Murdoch, Westmead, Woolloongabba
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Adelaide, Box Hill, Clayton, Footscray, Melbourne, Newtown, North Terrace, Parkville
2022-07-22
Active, closed
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097Multiple Myeloma
DrugsTalquetamab·Carfilzomib·Pomalidomide·Daratumumab
Janssen Research & Development, LLC
Phase 1
166
Fitzroy, Melbourne, Southport, Wollongong
2021-09-22
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Camberwell, Hobart, Liverpool, Maroochydore, Melbourne
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
Camperdown, Fitzroy, Heidelberg, Herston, Melbourne, Murdoch, Waratah, Westmead
2021-08-19
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
1,054
Adelaide, Hobart, Melbourne, Sunshine Coast
2021-06-17
Active, closed
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146Multiple Myeloma
DrugsNirogacestat·Teclistamab·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 1
140
Fitzroy, Melbourne, Waratah
2021-03-12
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
DrugsAbiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
696
Birtinya, Darlinghurst, Herston, Hobart, Kurralta Park, Liverpool, Melbourne, Murdoch
2020-09-23
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
419
Adelaide, Camperdown, Herston, Melbourne, Murdoch
2020-06-12
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
629
Camperdown, Frankston, Kogarah, Melbourne, Murdoch
2018-03-23
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
700
Adelaide, Coburg, Concord, Heidelberg, Melbourne, Perth, Prahran, Wahroonga
2013-09-09
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-australia/city/melbourne

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in Melbourne that also match the filters currently applied.

How many clinical trials are recruiting in Melbourne?

13 of the 37 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Melbourne), 37 studies
PhaseStudiesRecruitingShare
Phase 319751.4%
Phase 112532.4%
Phase 2308.1%
Phase 1/2102.7%
Phase 2/3112.7%
Phase 4102.7%

Most active sponsors

Lead sponsors with the most studies (Melbourne)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC3713
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.